Researchers have found that a new cancer treatment called pelareorep shows significant promise for people with a difficult-to-treat form of metastatic colorectal cancer (mCRC). In a recent study, patients with KRAS-mutant, microsatellite-stable mCRC experienced a median duration of response of 19.5 months when treated with pelareorep in combination with other therapies. This is a remarkable improvement compared to the historical benchmark of just 4 to 6 months for this patient population.

This finding is particularly important for those seeking effective options for cancer treatment. With a response rate of 33% in patients receiving the pelareorep combination therapy, this treatment could potentially offer a longer-lasting solution for individuals battling this aggressive form of cancer. The results suggest that pelareorep could help extend the time during which patients experience a positive response to treatment, which is crucial for improving quality of life and survival rates.

The evidence comes from a Phase 2 clinical trial, which is an early-stage study that evaluates the effectiveness of a treatment in a specific patient group. While the results are promising, they are not yet definitive, and further research is needed to confirm these findings in larger populations. Oncolytics Biotech, the company behind pelareorep, is currently working with the U.S. Food and Drug Administration (FDA) to explore an accelerated approval pathway based on these encouraging results.

For those interested in the latest cancer treatments, it’s worth keeping an eye on developments related to pelareorep. While it’s still in the trial phase, the potential for a treatment that significantly improves response duration could change the landscape for individuals with KRAS-mutant mCRC.

Source: globenewswire.com